During the extensive clinical evaluation of Bevacizumab, as monotherapy or concomitant with other anti-cancer treatments, VEGF measurements have been done in different biological fluids including serum or plasma [7, 8, 23] as well as other compartments such as platelets' interior [24]. This evidence concerns the gene VEGFA and cancer.